$10.20
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Prices $100 Million Public Offering
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Overview
52-week range
$5.46
$16
44% of range
Avg surprise (last 3)
-39.8%
Avg reaction (last 2)
-15.9%
50% positive
Latest IV / EM
145%
EM ±33.6% · $10 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-1.72 | $-1.36 | -26.5% | -1,533% | -37.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.20 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.38 | $-1.13 | -22.1% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $0.12 | $0.41 | -70.7% | — | +6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.17 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.05 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.66 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | $0.12 | -$1.38 | +108.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | $12M | $11M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-83M | — | $-52M | $-63M | $12M | — | $-62M | $-56M |
| Net income | $-90M | — | $-62M | $-71M | $6M | — | $-60M | $-53M |
| EPS (diluted) | $-1.72 | — | $-1.20 | $-1.38 | $0.12 | — | $-1.17 | $-1.05 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15M | $34M | $59M | $80M | $130M | $58M | $57M | $58M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $187M | $281M | $332M | $374M | $313M | $278M | $313M | $347M |
| Total assets | $342M | $453M | $525M | $581M | $491M | $466M | $519M | $569M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $321M | $350M | $364M | $367M | $217M | $206M | $218M | $221M |
| Total equity | $21M | $103M | $161M | $214M | $274M | $260M | $301M | $348M |